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Abstract: Amphetamine derivatives such as methamphetamine (METH) and  
3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are widely abused drugs in a 
recreational context. This has led to concern because of the evidence that they are 
neurotoxic in animal models and cognitive impairments have been described in heavy 
abusers. The main targets of these drugs are plasmalemmal and vesicular monoamine 
transporters, leading to reverse transport and increased monoamine efflux to the synapse. 
As far as neurotoxicity is concerned, increased reactive oxygen species (ROS) production 
seems to be one of the main causes. Recent research has demonstrated that blockade of α7 
nicotinic acetylcholine receptors (nAChR) inhibits METH- and MDMA-induced ROS 
production in striatal synaptosomes which is dependent on calcium and on NO-synthase 
activation. Moreover, α7 nAChR antagonists (methyllycaconitine and memantine) 
attenuated in vivo the neurotoxicity induced by METH and MDMA, and memantine 
prevented the cognitive impairment induced by these drugs. Radioligand binding 
experiments demonstrated that both drugs have affinity to α7 and heteromeric nAChR, 
with MDMA showing lower Ki values, while fluorescence calcium experiments indicated 
that MDMA behaves as a partial agonist on α7 and as an antagonist on heteromeric nAChR. 
Sustained Ca increase led to calpain and caspase-3 activation. In addition, modulatory effects 
of MDMA on α7 and heteromeric nAChR populations have been found.  
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1. Introduction 
Methamphetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are 
amphetamine derivatives (Figure 1) that are widely abused in developed countries, due their potent 
stimulating effects on the central nervous system. They are usually taken in a recreational context, 
producing feelings of euphoria, well-being and connectedness with others, enhancing sensitive 
perceptions and personal relationships. The widespread use of these drugs has led to concern because 
of the extensive evidence that they are neurotoxic in animal models (for reviews, see [1-4]). The 
neurotoxic consequences of the acute or long-term use of these substances in humans are still uncertain 
and a great deal of research is being done on the subject. In fact, cognitive impairment and 
dopaminergic/serotonergic deficits have been described in chronic abusers of these drugs [5-10]. A 
recent meta-analysis on the effects of MDMA on short-term and working memory [11] concludes that 
ecstasy users perform significatively worse in all memory domains, both in studies using drug-naïve 
controls and studies using polydrug controls, and that this impairment is related to total lifetime 
ecstasy consumption. It is a consistent finding that ecstasy users display significantly more 
psychopathology than non-users. The relationship is the most evident for depression, anxiety, phobias, 
psychotic symptoms, somatization, aggression, hostility, impulsiveness and sensation seeking 
behaviour (reviewed by [5]). However, the results of these studies are biassed by the fact that it is 
practically impossible to find exclusive MDMA consumers, but it is taken associated with other drugs 
such as cannabis, cocaine, alcohol, etc., which can modify its psychiatric effects.  
Long-term damage to dopaminergic and serotonergic nerve terminals after chronic abuse of METH 
and MDMA has been reported by a number of preclinical studies in several brain areas. Concretely, 
treatment with METH induces long-lasting depletion in the striatal content of dopamine (DA) and its 
metabolites [12], decrease in tyrosine hydroxylase activity [13,14] and loss of dopamine transporters 
(DAT) [15,16]. On the other hand, the deleterious effects of MDMA have been found to affect  
more specifically serotonergic terminals in rats and primates, with little effect on dopaminergic 
terminals [17,18]. Conversely, MDMA behaves as a dopaminergic neurotoxin in mice, with additional 
serotonergic depletions [19]. 
From the first time it was reported, the study of the mechanisms of neurotoxicity induced by 
amphetamine derivatives has generated an important amount of works. Although some aspects are still 
awaiting an explanation, there is a clear evidence of the coordinate action of several key phenomena 
that contribute to such effects, namely vesicular (VMAT-2) and plasmalemmal dopamine transporters 
(DAT) function, mitochondria and energy balance, glutamate, dopamine receptors, hyperthermia and 
reactive oxygen species (ROS) (reviewed by [20]). Since the role of ROS was proposed by Gibb and 
co-workers in 1989 [21], subsequent works have demonstrated that these species seem to be the final 
executors of neuronal damage, reacting with functional and structural molecules and inducing 
degenerative changes. ROS can originate from the auto-oxidation of cytosolic DA [22], glutamate 
excitotoxiciy leading to mitochondrial dysfunction and nitric oxide (NO) production [23,24], 
activation of D1 receptors within the striatum leading to increases in nNOS mRNA expression [25]; 
and inhibition of mitochondrial function increasing mitochondrial-mediated ROS generation. Also, 
activation of microglia (source of reactive species) has been reported after METH  
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treatment [15,17,26,27] but not after MDMA [17]. Additionally, a role of a metabolic reactive 
derivative of MDMA in the neurotoxic process has been proposed [28]. 
Figure 1. Chemical structures of the main compounds cited in this article. 
 
According to the ROS hypothesis an in vitro model using rat striatal synaptosomes was set up to 
induce and detect the production of these species using flow cytometry and a ROS-sensitive 
fluorescent probe [29]. This provided a system where the participation of several signalling pathways 
in ROS production could be studied. The fact that the nicotinic acetylcholine receptor (nAChR) 
antagonist methyllycaconitine (MLA) blocked METH-induced ROS in this model pointed to a new 
mode of action of amphetamines that deserved further research. In this article we will review and 
integrate all the evidence concerning the role of neuronal nicotinic receptors in the mode of action of 
amphetamine derivatives. 
2. Some Generalities about nAChR 
Neuronal nAChR belong to the superfamily of ionotropic receptors and include a number of 
subtypes formed by the association of five subunits encoded by different genes. To date, the genes that 
have been cloned include two subfamilies of nine α (α2-α10) and three β (β2-β4) subunits and are 
expressed in the nervous system, cochlea and a number of non-neuronal tissues [30-32]. nAChR 
subunits assemble in pentamers which can be homomeric or heteromeric, forming a central ion pore 
with different structural, functional and pharmacological properties [33]. Two main classes have been 
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identified: the α-bungarotoxin (α-BgTx)-sensitive receptors, which are made up of the α7, α8, α9 
and/or α10 subunits and can form homomeric or heteromeric receptors, and α-BgTx-insensitive 
receptors that consist of α2-6 and (β2-4) subunits, and bind nicotine and many other nicotinic agonists 
with high affinity but not α-BgTx [34]. 
Depending on their subunit composition nAChRs are permeant to the cations Na+ and K+or Ca2+ 
(reviewed in [35]). Thus heteromeric nAChR made of α and β subunits have in general a low 
permeability for Ca2+ (fractional current of 2-5%). By contrast, homomeric α7 subtypes have the 
highest fractional Ca2+ current, which ranges from 6% to 12% depending on the species. An important 
issue is the fact that the fractional Ca2+ current through human α7 nAChR is the highest reported for 
homomeric ligand-gated receptors, matching that of heteromeric NMDA receptors [36]. Also, 
depolarisation induced by entry of Na+ or Ca2+ could induce voltage-gated-calcium channels opening 
and enhance Ca2+ influx. These two mechanisms can be physiologically complementary and play 
important roles in cell signalling by activating different downstream intracellular neuronal pathways 
(reviewed in [37]) such as protein kinase C (PKC) and neuronal nitric oxide synthase (nNOS), which 
have similarly been implicated in the neurotoxicity of amphetamines [38,39]. 
nAChR have a number of allosteric binding sites in addition to the ACh binding sites. Thus several 
compounds with different chemical structures have been found to bind to these sites and behave as 
allosteric modulators of nAChR function (reviewed in [40]). 
The brain functions were nAChR play a role include cognition, locomotion and analgesia [41-44] 
and nicotine addiction [45]. In the CNS nAChR are mainly located presynaptically modulating the 
release of almost all neurotransmitters, including dopamine, but also have a post-synaptic localization 
in some areas, where they mediate fast synaptic transmission [34,37,40]. 
3. Role of nAChR in METH- and MDMA-Induced ROS Production 
3.1. ROS and Amphetamine Neurotoxicity 
The preponderant role of ROS in METH- and MDMA-induced neurotoxicity has been extensively 
demonstrated by the fact that inhibition of their formation or preventing their action affords 
neuroprotection against these substances. Thus, enhancement of the antioxidant resources of the cells 
such as glutathione peroxidase [46] or isoforms of superoxide dismutase [47,48] is neuroprotective 
against amphetamine derivatives. Also, antioxidants as selenium and melatonin, [49,50], L-carnitine [51], 
N-acetylcysteine [52] or the endogenous antioxidant carnosine [53] are also neuroprotective against 
this damage. 
In addition, amphetamine derivatives induce in vivo a significant increase in body temperature 
which is potentiated by a high ambient temperature [53], as a consequence of their central  
thermo-disregulatory effect. It has been suggested that hyperthermia might also potentiate the 
production of 6-hydroxydopamine or related ROS after drug exposure [54] or potentiate the propagation 
of ROS damage to lipids. Thus hyperthermia potentiates amphetamines’ neurotoxicity [55], and it has 
been demonstrated that reducing hyperthermia attenuates long-term decreases in DA and 5-HT  
content [56]. For this reason it was lately found that the neuroprotective effects afforded by some 
drugs was due to their reduction of hyperthermia rather than to an effect on its main pharmacological 
target [57,58]. Therefore it was necessary to set up an in vitro model where ROS production could be 
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induced and the interferences of an antihyperthermic effect could be avoided. This allowed testing the 
role of determined pathways in METH- and MDMA-induced ROS production without such 
interferences. 
3.2. Mechanisms Involved in ROS Production Induced by METH and MDMA in Striatal Synaptosomes 
The effect of METH and MDMA addition on ROS production was studied using a preparation of 
semi-purified rat striatal synaptosomes loaded with the ROS-sensitive fluorescent probe  
2’,7’-dichlorofluorescin diacetate (DCFH-DA) and a flow cytometer equipped with an argon laser as 
the measurement instrument [29,79]. 
METH increased DCF fluorescence when added to synaptosomes, indicating that it induces ROS 
production in neuron terminals (Figure 2). This increase was measured inside the synaptosomes and 
not in the medium, due that flow cytometer measures the fluorescence associated with each particle. It 
has been established that acute incubation of synaptosomes with METH causes release of dopamine from 
presynaptic nerve terminals and inhibits DA uptake, probably by reversion of DAT functionality [59]. 
Released DA can undergo oxidation and generate ROS but, as only the fluorescence associated with 
synaptosomes was measured; this putative source of ROS was not taken into account. Moreover, if 
ROS formation took place mainly in the extracellular medium this would not explain the specificity of 
METH degeneration for DA terminals, in that the oxidation of extraneuronal DA would be expected to 
nonspecifically damage all neighboring neurons, not just the dopaminergic. Thus, this model allowed 
describing an intracellular oxidative effect of METH that was more likely to induce selective damage 
to dopamine terminals. 
Figure 2. Representative fluorescence flow cytometry histograms and dot plots depicting 
the increase in ROS (DCF fluorescence) induced by previous incubation of rat striatal 
synaptosomes with METH or MDMA [29,79]. The histograms shift to the right (higher 
fluorescences) as well as individual synaptosomes show higher fluorescence intensity. 
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Several authors point to dopamine as one of the main sources of ROS induced by amphetamines [60,61]. 
When synaptosomes from previously DA-depleted rats (treated with reserpine or reserpine plus  
α-methyl-p-tyrosine) were tested the METH-induced ROS production was inhibited [29]. These results 
corroborate DA as the main source of the measured ROS. METH, by altering the intracellular pH 
gradient, prevents the function of the vesicular monoamine transporter (VMAT) and promotes DA 
release from vesicles to cytosol [62] where it can be oxidized. Accordingly, in vitro incubation of  
non-depleted synaptosomes with substances that block VMAT (reserpine) prevented METH oxidative 
effect [29]. 
Nitric oxide (NO) and peroxynitrite (ONOO−) are two reactive species that play a key role in the 
neuronal damage induced by amphetamine derivatives. A number of in vivo studies demonstrate the 
involvement of neuronal nitric oxide synthase (nNOS) in METH neurotoxicity. Thus, METH 
administration causes overexpression of nNOS in mouse striatum [38]. NO is an inhibitor of 
mitochondrial respiratory chain complexes II and IV and rapidly reacts with superoxide to yield 
ONOO−, which is a powerful oxidant and a potentially irreversible inhibitor of complexes II and III. 
The ONOO− formed inside mitochondria impairs mitochondrial functions and integrity. Also ONOO− 
oxidises glutathione, α-tocopherol and ascorbate, thereby compromising essential antioxidant pools 
within mitochondria [63,64]. NO and Ca2+ synergistically inactivate mitochondrial complex I and 
cause a loss of cytochrome c, probably via formation of ONOO− [65]. 
In this striatal synaptosomes model, the inhibitor of nNOS, 7-nitroindazole, completely abolished 
METH-induced ROS production, demonstrating a role of this enzyme in METH oxidative effects. 
Activation of nNOS produces NO, which reacts with the peroxide radicals which would originate from 
DA autooxidation, producing the more toxic radical peroxynitrite. This oxidant has been found to 
inhibit DAT functionality [66,67]. Such an inhibition would favour cytosolic DA accumulation, which 
would increase oxidative species inside the synaptosomes. Peroxynitrite has been postulated as  
the main species responsible for the damage in cell structures [66]. Accordingly, inhibition of NO 
formation through a variety of methodological approaches has confered neuroprotection against METH 
or MDMA: nNOS deficient mice are resistant to METH-induced dopaminergic neurotoxicity [68]; 
administration of NO synthase inhibitors such as S-methylcitrulline or AR-R17477 attenuates the 
dopaminergic and serotonergic neurotoxicity of MDMA and METH [69-73]. Finally, selenium (more 
effective as a scavenger of two-electron oxidants, such as ONOO− and not particularly reactive 
towards single electron oxidants, such as NO and superoxide) shows a high neuroprotective effect 
against METH-induced neurotoxicity [74]. 
Kinases such as protein kinase C (PKC) have been implicated in various aspects of DAT function 
and direct phosphorylation [75]. It has been described that PKC contributes to DAT phosphorylation 
producing an impairment of its function [76-78]. Accordingly, in the synaptosomes model, inhibition 
of PKC fully prevented METH-induced ROS [29], corroborating a key role of PKC in this process. 
The prevention by the PKC inhibitor could be explained by the maintenance of DAT function, which 
would be capable of releasing the increased cytoplasmatic dopamine to the extracellular medium, thus 
avoiding its conversion to ROS inside the terminal. 
 
Pharmaceuticals 2011, 4                
 
 
828
Figure 3. Schematic representation of the pathways involved in oxidative stress and 
neurotoxicity induced by amphetamine derivatives (AD). Activation of α7 nAChR by AD 
contributes, together with other proposed pathways (i.e., NMDA receptor activation [61,71]), 
to a raise in intracellular Ca2+ which results in activation of nNOS and production of NO. 
NO can produce ONOO− by reacting with superoxide. ONOO− induces direct damage to 
cell structures and induces mitochondrial dysfunction leading to metabolic impairment and 
cytotoxicity. Also ONOO- induces nitration of the plasmalemmal and vesicular monoamine 
transporters (MAT and VMAT, respectively). Ca2+ also activates calpain and caspase 3 
(see section 7.2), which are involved in proteolysis and cell death mechanisms, as well as 
PKC, which is related to MAT blockade trapping DA inside the terminal. At the same 
time, AD induce increase in free intracellular DA that can be metabolised by MAOB to 
H2O2 and superoxide which in turn can be further converted via the Fenton reaction to 
hydroxyl radicals that contribute to oxidative stress. Also dopamine can be metabolised to 
reactive quinone derivatives which contribute to cell function impairment [60]. Finally 
additional cytosolic Ca2+ can enter after depolarisation through voltage-operated calcium 
channels (VOCC) or can be released from the endoplasmic reticle. 
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Similar results as above have been obtained with METH and MDMA on mouse striatal 
synaptosomes [79,80]. The concentration-response curve of MDMA showed an inverted U-shape, with 
maximal pro-oxidative activity between 50 and 100 μM, declining at higher concentrations. An 
explanation for this effect is given by the fact that, at concentrations above 100 μM, MDMA inhibits 
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monoamine oxidase B (MAO-B), which is responsible for enzymatic dopamine degradation generating 
hydrogen peroxide. In fact, pharmacological inhibition of MAO-B by L-deprenyl abolished the 
oxidative effect of 50 μM MDMA. 
Taken together, in the synaptosomes model an increase in cytosolic DA and activation of nNOS and 
PKC (blocking DA transport through DAT) are needed to generate ROS inside the dopaminergic 
terminal. Moreover, both PKC and nNOS are enzymes that require calcium to be activated. 
Consequently, when calcium of the medium is chelated with EGTA, the oxidative effect of METH and 
MDMA is prevented in this model. 
To sum up, an integrative mechanism by which METH/MDMA induce ROS production in striatal 
synaptosomes was postulated: the drug enters the synaptosome, either by passive diffusion or through 
DAT, as in the case of MDMA (cocaine, a DAT blocker, prevented MDMA but not METH oxidative 
effect [81]), and promotes DA release from synaptic vesicles to the cytosol. Increased cytosolic DA 
can suffer from autoxidation and generate initial ROS which can modify DAT function. Additionally, 
there is an increase in intrasynaptosomal Ca2+, which would activate nNOS and PKC. PKC activation 
would lead to phosphorylation of proteins such as DAT promoting, together with ONOO−, a reduction 
of DAT activity and accumulation of cytosolic DA that would impair the initial oxidative stress. 
Looking at this hypothesis, a key point remained to be addressed: the mechanism by which METH 
and MDMA increased cytosolic calcium. The L-type voltage-gated calcium channel blocker, 
nitrendipine, and the inhibitors of calcium release from the endoplasmic reticulum, dantrolene  
and 2-aminoethoxydiphenylborate (2-APB), inhibited MDMA-induced ROS in mouse striatal 
synaptosomes [81]. This, in agreement with extracellular Ca2+ chelation experiments, suggested that 
there had to be a preceeding depolarizing event induced by METH/MDMA that triggered the opening 
of voltage-gated channels or calcium-induced calcium release from the endoplasmic reticulum. 
Figure 4. ROS induction by METH in striatal synaptosomes and its inhibition by α7 
nAChR antagonists [29] (MLA and α-bungarotoxin, BGT). The α4β2 antagonist  
dihydro-β-erythroidine (DBE) was devoid of effect. 
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Liu et al. [82] had reported that D-amphetamine enhanced Ca2+ entry and catecholamine release in 
bovine adrenal chromaffin cells via the activation of a nicotinic receptor resembling the α7 subtype. In 
addition, Skau and Gerald [83] had described that D-amphetamine inhibits α-bungarotoxin binding at 
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the neuromuscular junction in mice, while Klingler et al. [84] more recently identified nAChR as one 
of the physiological targets of MDMA in the neuromuscular junction. This led to test the α7 nAChR 
antagonist methyllycaconitine (MLA) and α-bungarotoxin on METH- and MDMA-induced ROS 
production in striatal synaptosomes. Both antagonists conferred protection against ROS production in 
our model [29,80], pointing to α7 nAChR as a putative new target to prevent amphetamines’  
oxidative damage. 
4. nAChR Modulate the Effects of METH and MDMA on Dopamine Transporters 
Acute treatment with METH or MDMA in rats induces an impairment of the uptake of radiolabeled 
neurotransmitters (i.e., dopamine and serotonin, 5-HT) in striatal synaptosomes, as a consequence of 
the rapid and reversible changes induced by these drugs on monoamine transporters. This effect can be 
reproduced by incubating in vitro the synaptosomes [77] with the drugs. For this reason the 
synaptosomal model described can be used to study the possible modulation of these effects by 
nicotinic ligands. 
[3H]5-HT uptake (in hippocampal) and [3H]DA uptake (in striatal synaptosomes) were measured as 
indicative of the acute serotonergic effect of MDMA and the acute dopaminergic effect of METH, 
respectively [29,79,80,88]. Preincubation of synaptosomes with MDMA (15 µM) induced a significant 
reduction in [3H]5-HT uptake by 40%. MDMA (10 µM) and METH (1 µM) also inhibited 
[3H]dopamine uptake by 75% and 80% respectively. This inhibition remained even after drug washout 
and therefore cannot be attributed to residual drug presence but to a persistent alteration of 
transporters. As incubation of drugs with synaptosomes was carried out in the presence of glutathione 
and a MAO-A inhibitor (chlorgiline), the effect of these drugs on monoamine transporters cannot be 
attributed to ROS. 
The effect of the amphetamine derivatives on these transporters was prevented by calcium chelation 
and inhibition of nNOS and PKC (both calcium-dependent enzymes). Some authors had already 
described the relationship between PKC and the effect of amphetamines on DAT [77]. Additionally, 
the physical association of nNOS and serotonin transporter (SERT) has been reported, resulting in 
modulation of SERT activity [85]. Also, Cao and Reith [86] described how NO inhibits DA uptake.  
Based on the results reported on ROS production, the α7 nAChR antagonists MLA and memantine 
were tested in this model [29,79,80], and found to prevent the effects of METH and MDMA on DAT. 
Memantine (see section 6 for further details on this drug) has a dual mechanism as glutamate NMDA 
receptor antagonist and as an α7 nAChR antagonist [91]. PNU 282987 (an α7 nAChR agonist) 
prevented the protective effect of MEM, but MK-801 (glutamate NMDA receptor antagonist) did not 
modify it, confirming that the effect of MEM on MDMA/METH-induced uptake inhibition is mediated 
by α7 nAChR and not by blockade of NMDA receptor. These results suggest that activation of nAChR 
alone or combined with other effects of amphetamine derivatives leads to the activation of pathways 
(i.e., nNOS or PKC) involved in monoamine transporter inhibition. 
Aznar et al. [87] described the presence of α7 nAChR at serotonin neurones, in terminals projecting 
to the hippocampus. Accordingly, PNU 282987 alone inhibited 5-HT uptake, which suggests that 
SERT functionality in the hippocampal serotonergic terminals can be regulated by α7 nAChRand 
potentiated the inhibitory effect of MDMA on SERT function [88,89]. 
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5. The α7 nAChR Antagonist MLA Protects In Vivo against METH and MDMA Neurotoxicity 
The next step was to assess whether the protective effects observed in vitro had an in vivo 
translation preventing or attenuating the amphetamine-induced damage. For this reason animal 
experiments were conducted treating mice with a classic neutoxic dosing schedule of METH  
(7.5 mg/kg s.c., every 2 h, for a total of four doses) or MDMA (25 mg/kg, s.c., every 3 h, for a total of 
three doses) and compared some of the main neurotoxicity markers with those from mice that had 
previously received MLA [79,80]. In both cases, an antihyperthermic effect of MLA was ruled out. 
METH induced, at 72 h post-treatment, a significant loss of striatal DA reuptake sites of about 73%, 
measured as specific binding of [3H]WIN 35428 in mouse striatum membranes [79,80]. This 
dopaminergic injury was attenuated in mice pretreated with MLA (from 73% to 43%) without 
affecting METH-induced hyperthermia. Also, MLA prevented the decrease in tyrosine hydroxylase, 
the key enzyme in dopamine synthesis whose loss is also correlated with dopaminergic impairment. 
Moreover, pretreatment with MLA prevented the striatal inflamatory glial activation assessed 24 h 
after treatment as an increase in [3H]PK 11195 specific binding.  
Similar results were obtained with MDMA and MLA (Figure 5). Surprisingly, MLA did not prevent 
the loss in [3H]paroxetine binding sites indicating that its neuroprotective effect in mice is selective for 
dopaminergic terminals [80]. This selective dopaminergic neuroprotection of MLA has been 
corroborated more recently by other researchers [90]. 
Figure 5. Protective effects of MLA on striatal dopaminergic neurotoxicity in mice treated 
with MDMA. The loss of dopamine transporters was quantified by [3H]WIN 35428 
binding (panel A) and the dopamine impairment was measured by Western blotting (panel 
B) using a primary antibody against tyrosine hydroxylase (reproduced from [79]). 
   
A                                                                              B 
6. Memantine, a Drug Used in Alzheimer’s Disease, Is also an α7 nAChR Antagonist and 
Protects In Vivo against METH and MDMA Neurotoxicity  
Memantine (MEM) is a non-competitive antagonist of the NMDA glutamate receptor that is 
currently being used to treat moderate-to-severe Alzheimer’s disease. It possesses voltage-dependent 
binding properties that confer the ability of reducing tonic (excytotoxic), but not synaptic, NMDA 
receptor activity. In addition it was found that MEM, at clinically relevant concentrations, blocks α7 
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nAChR in a non-competitive manner, even more effectively that it does at NMDA receptors [91]. 
Accordingly, Unger et al. [92] had described how treatment with MEM significantly increases the 
number of α7 nAChR binding sites in frontal and retrosplenial cortex in mice, suggesting the 
interaction of MEM with these nicotinic receptors, as up-regulation of nAChR is a characteristic effect 
induced by nicotinic ligands (agonists and antagonists, see point 9 for further information). 
The use of MLA as a medicine in humans could be precluded by its chemical complexity and toxic 
side effects [93,94]. By contrast, if MEM, due to its dual mechanism, prevented METH and  
MDMA-induced neurotoxicity in rodents, it could be proposed as a treatment in humans to prevent the 
effects of these amphetamine derivatives or even to treat addiction. Moreover, it might also have a 
beneficial effect on the memory impairment that abusers of these drugs usually suffer from [95,96]. 
Accordingly the effect of MEM on dopaminergic neurotoxicity (characteristic of METH and 
MDMA in mice) was studied using the in vitro striatal synaptosomes model [88,89]. MEM had not 
direct antioxidant properties against H2O2 but, at low (0.3 μM) micromolar concentrations, inhibited 
the ROS production induced by MDMA and METH. This inhibition was countered by the presence of 
PNU 282987, a specific agonist of the α7 nAChR, and was not modified by glutamate agonists in the 
incubation medium, indicating that the protective effect took place through α7 blockade.  
In vivo experiments were conducted administering MDMA to Dark Agouti rats (18 mg/kg, s.c.) as a 
model of serotonergic neurotoxicity induced by MDMA [88,89]. Dark Agouti rats (a strain devoid of 
some CYP isoforms) suffer a significant serotonergic lesion in response to just a single dose of 
MDMA [97], conversely to what occurs with the more usual strains, needing several doses to show a 
similar injury [98]. Studies in mice adminsitered with METH were also carried out to study the effect 
of MEM on dopaminergic METH-induced neurotoxicity. MEM (5 mg/kg, i.p.) was administered  
30 min before the corresponding dose of MDMA or METH and did not modify the hyperthermic 
response in any of the cases. 
A significant decrease in the density of serotonin transporters (assessed by [3H]paroxetine binding) 
was observed in the hippocampus and frontal cortex of MDMA-treated rats killed 7 days post-treatment, 
although such a serotonergic injury was already apparent 24 h post-treatment [89]. In both cases, 
MEM significantly prevented the loss of binding sites, suggesting a neuroprotective effect on 
serotonergic terminals (Figure 6). MEM also prevented the delayed glial activation that was detected 
as an increase in [3H]PK 11195 binding in the animals killed 7 days after treatment, supporting the 
protective effect. 
Different transcription factors such as the nuclear factor kappa B (NF-kB) can be activated after 
increased ROS production. NF-kB induces the expression of pro-inflammatory and cytotoxic genes 
and plays a key role in the balance between cell survival and death. The translocation (from cytosol to 
the nucleus) of P65, the active subunit of NF-kB, was measured in the hippocampus of differently 
treated rats, detecting a significant increased p65 nuclear translocation in the hippocampus of  
MDMA-treated animals, which indicates activation of NF-κB. P65 translocation was inhibited by 
MEM pretreatment; suggesting that activation of NF-kB after treatment with MDMA participates in 
the cytotoxic effect, since when this activation is blocked by MEM, neuronal injury is prevented. As 
for dopaminergic damage is concerned, MEM also prevented the loss in [3H]WIN 35428 binding and 
tyrosine hydroxylase, as well as the microglial response [89]. 
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Figure 6. Prevention by memantine of the loss of serotonergic terminals induced by 
MDMA [89]. Dark Agouti rats were treated with a neurotoxic dose of MDMA plus/minus 
memantine (MEM) and killed 1 or 7 days after. [3H]paroxetine binding was performed in 
hippocampal membranes. ANOVA: * P < 0.05, *** P < 0.001 vs. saline; ### P < 0.001  
vs. MDMA.  
 
MEM showed a better protective effect in front of MDMA- and METH-induced neurotoxicity than 
MLA, which is a more specific α7 nAChR antagonist. Although MEM could directly prevent the 
MDMA- and the METH-induced neurotoxicity through antagonism at NMDA receptors, this is not a 
feasible hypothesis since antagonists of these receptors fail to prevent the oxidative stress and cell 
death induced by METH and MDMA [99]. However, the dual antagonism that MEM exerts on NMDA 
receptor and on α7 nAChR probably turns it into a better pharmacological tool to prevent 
amphetamines-induced damage in vivo. Firing of dopamine neurons is modulated by glutamatergic 
(excitatory) afferents and DA release is evoked by NMDA. If MEM blocks NMDA receptors, a 
decrease in extracellular DA levels would take place. Following the integrated hypothesis by  
Sprague et al. [100], the probability that released DA might be taken up into the depleted 5-HT 
terminals would be reduced by MEM. Consequently, the antagonism at NMDA receptors could 
contribute to the protective effects of MEM. Moreover, it has been recently reported that glutamate 
release induced by METH is abolished by MLA, indicating that it is triggered by α7 nAChR  
activation [90]. Therefore memantine would inhibit both glutamate release and NMDA receptor 
activation, showing enhanced neuroprotective properties when compared with MLA. 
7. Memantine Prevents the Cognitive Impairment Induced by METH and MDMA 
Having observed the neuroprotective effects of MEM, the next step was to investigate whether this 
drug could prevent the cognitive deficits induced by the amphetamine derivatives. There were carried 
out experiments to demonstrate a specific effect of MDMA or METH treatment and the possible 
modulation by MEM on the object recognition memory test and the Morris water maze, using Long 
Evans rats [101,102]. The animals pre-treated with MEM did not show the memory impairment  
that appeared in MDMA- or METH-treated animals. Therefore MEM, by preventing MDMA or  
METH-induced neuronal injury, contributes to attenuate the cognitive impairment produced by 
amphetamine derivatives. This preventive effect on memory impairment suggests a novel therapeutic 
approach to the treatment of CNS long-term adverse effects of amphetamine derivatives. 
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8. Amphetamine Derivatives Directly Interact with nAChR 
Looking at the effects found in vitro and in vivo it was necessary to investigate if METH and 
MDMA had affinity for nAChR. For this reason radioligand binding experiments were carried out 
using [3H]epibatidine to label heteromeric receptors and [3H]MLA to label homomeric α7. METH and 
MDMA displaced both [3H]epibatidine and [3H]MLA binding in PC12 cells and mouse brain 
membranes, indicating that they can directly interact with nAChR [103]. MDMA displayed higher 
affinity than METH for both subtypes of nAChR. The resulting Ki values fell in the micromolar range, 
some in the low micromolar range and others in the high micromolar range (Table 1). 
Table 1. Ki values of METH and MDMA against [3H]MLA and [3H]epibatidine binding in 
PC12 cells and mouse brain. nH is the Hill coefficient. * P < 0.05 and ** P < 0.01 vs. 1 
(one sample t test). Data reproduced from [103]. 
 PC12 cells Mouse brain 
Drugs 
Ki (μM) nH Ki (μM) nH [3H]MLA  
METH 283 ± 109 1.20 ± 0.15 369.77 ± 95.61 0.29 ± 0.08 ** 
MDMA 15.35 ± 1.03 1.35 ± 0.11 34.21 ± 6.71 0.40 ± 0.27 * 
 [3H]Epibatidine   
METH 155.36 ± 5.36 0.76 ± 0.11 23.90 ± 2.65 1.27 ± 0.28 
MDMA 25.71 ± 3.13 0.92 ± 0.04 0.76 ± 0.11 0.83 ± 0.12 
Special attention must be paid in the affinity for heteromeric receptors (Ki about 0.7 µM) which is 
practically the same that the Ki displayed by MDMA for the serotonin transporter, its main 
physiological target (0.61 µM) [98]. Therefore an interaction of MDMA on heteromeric nAChR at 
recreational doses is certainly possible. The fact that the lowest Ki values were found against 
[3H]epibatidine binding indicates that METH and MDMA displayed higher affinity for heteromeric 
nAChR which are the most abundant in the CNS. Also, similar results were found in rat brain 
membranes in which the Ki of MDMA and METH for α7 nAChR was around 9 and 4 μM, respectively. 
9. METH and MDMA Induce Up-Regulation of Nicotinic Receptors 
After prolonged contact with an agonist (i.e., nicotine) nAChR exhibit a particular regulation: 
contrarily to what is generally expected after continuous stimulation, a down-regulation, these 
receptors develop an increase in ligand binding (up-regulation) [104,105]. A number of works have 
been focused in the study of the complex mechanisms involved in such up-regulation of nAChR 
(reviewed by [106]). nAChR up-regulation could be a response to the desensitization that follows the 
constant presence of an agonist [107], in order to restore necessary nicotinic transmission. 
The mechanism through which nicotine induces nAChR up-regulation is complex and not fully 
clarified to date. There are reports indicating that nicotine-induced increases in nAChR are not 
accompanied by changes in mRNA encoding for the different subunits [108,109]. This led to other 
hypotheses, such as reduced receptor turnover, promotion of the assembly and migration to the  
plasma membrane of pre-existing intracellular subunits [110] or decrease in the rate of receptor 
turnover [111]. More recently, Sallette et al. [112] demonstrated that nicotine acts as a maturation 
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enhancer (chaperone) of those intracellular nAChR precursors that would otherwise be degraded. 
However, different authors show controversial results. Vallejo et al. [113] reported that α4β2  
up-regulation by nicotine is due to an increase/stabilization of the proportion of receptors in a high 
affinity state and not to an enhancement in receptor maturation.  
Regardless of the mechanism, according to competition experiments demonstrating the affinity of 
METH and MDMA for nAChR, it could be hypothesized that the up-regulation of nAChR induced by 
these drugs would follow a similar mechanism than that of nicotine: binding to immature forms of the 
receptor inhibiting their degradation, promoting their migration to the plasma membrane or stabilizing 
the high-affinity state. 
Accordingly, it was tested whether METH and MDMA had any effect on α7 and heteromeric 
nAChR binding densities in PC12 cells and found that both were increased in a time- and 
concentration-dependent manner [103] (Figure 7). Additional experiments with selective inhibitors 
were performed in order to ascertain the underlying mechanism, pointing that METH and MDMA  
up-regulate nAChR through a complex post-transcriptional process but in a similar manner than 
nicotine. Moreover, the work done to date indicates that up-regulation can occur if the drug has a 
particular affinity to one or more nAChR subunits; regardless of its agonist/antagonist properties (i.e., 
the antagonist DHBE is also able to induce it [114]). In addition, up-regulation is enhanced when the 
drug crosses the cell membrane to interact with immature forms of the receptor [115]. The affinity of 
METH and MDMA for both heteromeric and α7 nAChRs has been demonstrated and these drugs can 
reach the cytosplasm after transport through the dopamine transporter [116,117], which is abundant in 
PC12 cells. Therefore, the interaction of METH and MDMA with immature receptor subunits is 
feasible to induce such up-regulation. 
Figure 7. Concentration (A, C) and time (B, D) dependence of METH- and  
MDMA-induced nAChR up-regulation in differentiated PC12 cellls. PC12 cells were 
differentiated with NGF and incubated for 24 h at different concentrations of drug or for 
different times at a concentration of 300 μM. Panels A and B show the effects on 
homomeric α7 receptors and C and D those on heteromeric receptors. 
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Preliminary in vivo experiments also suggest that certain MDMA dosing schedules induce nAChR 
up-regulation in brain and potentiate the regulatory effects of nicotine [117]. 
10. Effects of METH and MDMA on nAChR Activation: Calcium and Electrophysiology 
Experiments 
10.1. Acute Effects 
Activation of nAChR in PC12 cells produces an increase in intracellular calcium, either directly 
(through α7 channels opening) or indirectly (after initial depolarization by heteromeric nAChR 
activation and opening of voltage-gated calcium channels) [118]. Garcia-Ratés et al. [119] used a 
fluorimetric method to investigate the effect of MDMA on Ca2+ levels in cultured PC12 cells and the 
involvement of different nAChR subtypes and other cell pathways related to Ca2+ mobilization [119]. 
MDMA acutely inhibited the effects of nAChR agonists (ACh, Nicotine and PNU 282987) (Figure 8A) 
but, when applied alone at low micromolar concentrations, induced a concentration-dependent increase 
in Ca2+. The effect of MDMA did not reach the maximum values induced by ACh, which indicates a 
partial agonist mode of action (Figure 8). The EC50 value was around 45 μM, which is in agreement 
with previous binding results. 
Figure 8. (A) Effect of increasing concentrations of MDMA on the responses to the 
nicotinic agonists ACh (100 µM), nicotine (100 µM) and PNU 282987 (0.1 µM) in PC12 
cells loaded with Fluo-4. MDMA was added to the cells 5 min before the agonist. Basal 
fluorescence levels were measured for 5 s before the agonist and for a further 60 s after its 
addition by means of an automated injector. (B) Representative concentration-response 
curves showing the increase in cytosolic Ca2+ induced by MDMA and ACh as a total 
agonist. Responses were normalized as % (Fmax-Fmin) and represented as a percentage of 
the maximum response (ACh 100 µM) for both curves. 
-7 -6 -5 -4 -3
0
25
50
75
100
125
PNU 282987
ACh
Nicotine
log [MDMA] (M)
Δ  C
a2
+
(%
 m
ax
im
al
 r
es
po
ns
e)
-9 -8 -7 -6 -5 -4 -3
0
25
50
75
100
125 ACh
MDMA
log [Drug] (M)
Δ  C
a2
+
(%
 m
ax
im
al
 r
es
po
ns
e)
A
B
 
Pharmaceuticals 2011, 4                
 
 
837
Electrophysiology experiments using Xenopus oocytes expressing human α7 and α4β2 nAChR also 
demonstrated an agonistic effect on α7 and an antagonist effect of MDMA on α4β2 nAChR [119]. 
The fact that MDMA induced an increase in cytosolic Ca2+ led to study the pathways involved 
using specific blockers. According to previous work [79], the α7 nAChR blockers MLA and  
α-bungarotoxin abolished the effect of MDMA, while the α4β2 antagonist dihydro-β-erythroidine did 
not modify it. Thus the increase in Ca2+ was initiated by activation of α7 nAChR and the binding affinity 
to α4β2 would be in agreement with the antagonist properties found in electrophysiology assays. A 
secondary implication of voltage-operated calcium channels and calcium-induced calcium release 
(CICR) from endoplasmic reticulum (ER) stores, which has been described to be coupled to α7 
nAChR activation, was also found [37,118]. 
The MDMA response was dependent on extracellular Ca2+, as suppression of this cation totally 
inhibited its effect. Extracellular Ca2+ could enter through either α7 channels or L-type voltage-operated 
calcium channels and, as stated above, this Ca2+ increase would also induce subsequent CICR. 
Although mechanisms other than nAChR activation cannot be totally ruled out in the MDMA-induced 
increase in cytosolic Ca2+, the practically complete inhibition by MLA and α-bungarotoxin indicates 
that α7 nAChR activation plays a major role in this process.  
10.2. Long Term Effects on Ca2+ Levels 
As nAChR are desensitized upon sustained stimulation the effect of 24 h-incubation with MDMA 
on basal Ca2+ levels was studied [119]. MDMA induced an increase in basal cytosolic Ca2+ levels, 
measured after drug washout. Surprisingly, pre-incubation with nicotine only increased basal levels 
when it was carried out for 1 h, but not after longer pre-incubation times. This indicates that cells are able 
to buffer sustained activation by nicotine, but not that induced by MDMA, which suggests increased 
vulnerability to this drug as it allows continous Ca2+ entry leading to an excitotoxic-like process. 
Sustained Ca2+ influx after MDMA could favor cytotoxicity through activation of Ca2+-dependent 
pathways (i.e., calpain). Calpain is a calcium-dependent protease whose activation is a primary 
mechanism that contributes to several types of neurodegenerative conditions, including the excitatory 
amino acid-induced neurotoxicity that is associated with traumatic brain injury, ischemia, and 
hyperthermia [120,121]. Calpain specifically degrades the cytoskeletal membrane protein, spectrin, 
into 145 and 150 kDa breakdown products [122]. Caspase 3 is another cysteine protease that is involved 
in apoptotic pathways. It also degrades spectrin but produces a 120 kDa spectrin fragment [123] and also 
can produce a 150 kDa fragment [124]. 
Incubation of PC12 cells with MDMA for 24 h induced a significant increase in spectrin breakdown 
products (SBDP) of 145 and 150 kDa, which indicates calpain activation, and a rise in the 120 kDa 
band that, together with the increase in the 150 kDa SBDP, points to caspase 3 activation (Figure 9). 
Moreover, the increases in SBDP induced by MDMA were prevented by MLA, indicating that α7 
nAChR play a key role in this process.  
10.3. Functional Up-Regulation 
In addition to radioligand binding up-regulation, nAChR can suffer changes in stoichiometry and an 
increase in functional state (functional up-regulation) after prolonged incubation with a ligand [106]. 
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Such up-regulation occurs also at a post-transcriptional level. When PC12 cells are incubated for 24 h 
with MDMA they exhibit increased responses to nicotinic agonists PNU 282987 (α7-selective) and  
5-I-A-85380 (selective for β2 subunit-containing receptors), measured after drug washout [119]. This 
indicates that MDMA also induces functional nAChR up-regulation.  
Figure 9. Representative Western blot of α-spectrin breakdown products (SBDP) 
originated by calpain activation (145 and 150 kDa) and capase 3 (120 and 150 kDa) after 
24 h treatment with culture medium (Ctrl), MDMA (50 µM), MDMA + MLA (10 nM) and 
MLA alone. The localization of the molecular weight (MW) markers is shown on the left 
of the picture. B. Quantification of dot intensity of the SBDPs. Data are the means ± SEM 
of three different cultures, loaded in duplicates. * P < 0.05 and ** P < 0.001 vs.  
control. Reproduced from [119].  
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11. Concluding Remarks, Future Perspectives 
Amphetamine derivatives are still a family of drugs with high incidence of abuse, mainly used with 
recreational and social purposes. Although they are believed to be safe by the users, there is clear 
evidence of cognitive impairment and dependence in frequent consumers [125]. In this review we have 
summarized a series of investigations that have added a new piece to the puzzle of the cellular effects 
of these drugs: the action on nicotinic receptors. An interesting point is the observation of prolonged 
calcium influx in cells (mediated by α7 nAChR) induced by MDMA, which leads to the activation of 
cytotoxic pathways and could account for long-term neurotoxic effects in frequent abusers. On the 
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other hand, despite the antagonist effect on heteromeric nAChR, the regulatory effect of that these 
drugs exert on nAChR densities could be responsible for certain neuropsychiatric disorders. 
One of the most interesting applications might be the possibility of preventing underirable effects, 
as demonstrated by the neuroprotection experiments. When it comes to a drug of abuse, the most 
advisable way of preventing undesirable effects is avoiding its intake. However, this new mechanism 
could provide additional strategies to treat or ameliorate the addiction or some of the deleterious 
effects caused by these drugs. 
Memantine has shown promising results in the treatment of amphetamine addiction [126]. No drugs are 
currently approved in the U.S. or Europe for the treatment of addictions to METH or MDMA. Fluoxetine 
pre-treatment has been recommended as protection from MDMA-induced long term neurotoxicity, but 
recently it has been found that fluoxetine decreases the clearance of MDMA and its metabolite, 
methylenedioxyamphetamine, leading to an increased risk of acute MDMA toxic effects [127]. 
MDMA was formerly used as a tool in psychotherapy, but its undesirable effects led to its 
withdrawal. Also, it has been assayed and proposed as a drug to treat anxiety disorders including  
post-traumatic stress [128]. The availability of a neuroprotective treatment could lead to reconsider or 
facilitate such applications. 
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